Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Lumenisity, a UK-based fibre optic and cabling supplier aligned to University of Southampton, closed a £7.5m ($9.7m) round on Wednesday led by BGF and featuring Parkwalk Advisors, the fund manager owned by commercialisation firm IP Group. The cash will go to building a new manufacturing and testing plant. Lumensity produces fibre optic cables using a hollow core technology which helps light propagate more effectively. Ena Respiratory, an Australia-based cold and flu medicine developer at University of Melbourne, has secured A$11.7m ($8.4m) in a round featuring multi-university venturing fund Uniseed that was led by Australian government-backed vehicle Medical Research Commercialisation Fund. The company has identified a small molecule that could serve as a nasal spray to boost the immune system almost immediately in combating the common cold and flu. Ena Respiratory claims the product could be rapidly manufactured should its efficacy be proven during clinical studies given the need for respiratory medicines to limit the effect on healthcare providers during the covid-19 pandemic. Ena Respiratory previously raised $4.7m from Uniseed and MCRF in 2017.  It extends research led by David Jackson, a professor in the Department of Microbiology and Immunology at University of Melbourne. Geospock, a UK-based big data analytics platform spun out of University of Cambridge,  secured $5.4m of series A funding on Friday co-led by Cambridge Innovation Capital, a VC investor focused on the Cambridge, UK ecosystem. NChain co-led the round with participation from telecoms firm NTT Docomo Ventures, a vehicle for mobile network operator NTT Docomo, backed the round alongside venture capital firm Global Brain. The funding will go to product development and expanding Geospock internationally. The spinout had raised $27.1m prior to the latest round, including $2.6m from investors including Parkwalk Advisors in March 2019. Nu Quantum, a UK-based quantum photonics spinout of University of Cambridge, today obtained £2.1m ($2.7m) in seed funding today led by Amadeus Capital Partners, with participation from tech transfer office Cambridge Enterprise, Cambridge researchers-founded Ahren Innovation Capital, Seraphim Capital, IQ Capital and Martlet Capital, the investment division for aerospace manufacturer Marshall of Cambridge. The money will fund a photonics lab in Cambridge and enable Nu Quantum to hire across several teams as it approaches commercial technology demonstration. Amadeus previously led an $840,000 pre-seed round in November 2019, when Cambridge Enterprise, IQ Capital, Ahren Innovation Capital and Martlet Capital also contributed. BioAesthetics, a US-based breast reconstruction graft technology spinout of Tulane University, has collected more than $2.5m of series A funding from investors…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?